Abstract
Randomized, open-label, cross-over, phase-3 study to evaluate efficacy and safety of LIB003 compared with evolocumab in homozygous familial hypercholesterolaemia patients on stable lipid-lowering therapy (liberate-HOFH)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have